- +1 551 333 1547
- +44 2070 979277
- live:skype_chat
3D Printing Drug Comprehensive Study by Type (Spritam, Others), Application (Neurology, Hearing and Audibility Aid, Dental, Medical Implants, Others), End User (Hospitals, Clinics and, Research Laboratory, Others)
3D Printing Drug Market by XX Submarkets | Forecast Years 2022-2027
Industry Background:
3D printed drugs are medicines that are designed using 3D printing technology to customize them for patients in safe and effective manner. These drugs possess unitary porous structural design that readily dissolve in the mouth, which prevent high-dosage medicines from being swallowed intact. Therefore, this type of medicine is useful for patients having swallowing difficulties such as children, elderly, and those ailing with Alzheimer’s disease, stroke complications, and other neurological disabilities.The Global 3D Printing Drug market presents a comprehensive analysis of the 3D Printing Drug market by product type (Spritam and Others), by end-user/application (Neurology, Hearing and Audibility Aid, Dental, Medical Implants and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. The key Vendors profiled in the report are Aprecia Pharmaceuticals (United States), Hewlett Packard Caribe (Netherlands), BV (Netherlands), LLC (United States), GlaxoSmithKline Plc. (United Kingdom), FabRx Ltd (United Kingdom) and Cycle Pharmaceuticals (United Kingdom).
| Attributes | Details |
|---|---|
| Study Period | 2017-2027 |
| Base Year | 2021 |
| Forecast Period | |
| Historical Period | 2017-2021 |
| Unit | Value (USD Million) |
| Key Companies Profiled | Aprecia Pharmaceuticals (United States), Hewlett Packard Caribe (Netherlands), BV (Netherlands), LLC (United States), GlaxoSmithKline Plc. (United Kingdom), FabRx Ltd (United Kingdom) and Cycle Pharmaceuticals (United Kingdom) |
| Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
3D Printing Drug Market Dynamics:
| Attributes | Details |
|---|---|
| Growth Drivers |
|
| Influencing Trends |
|
| Restraints |
|
| Road Blocks / Challenges |
|
| Gaps & Opportunities |
|
Regional Breakdown and Segment Analysis
This section of our report presents a realistic picture of the Global 3D Printing Drug industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in the geographical region of interest. The End User, such as Hospitals, is boosting the 3D Printing Drug market and is anticipated to experience a steady growth during the forecast period.
The key manufacturers are targeting the innovations of the products with better quality, better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking upon mergers and acquisitions in order to maintain their presence in the market
The regional segmentation covered in this report are:
Report Objectives / Segmentation Covered
By Type
- Spritam
- Others
By Application
- Neurology
- Hearing and Audibility Aid
- Dental, Medical Implants
- Others
By End User
- Hospitals
- Clinics and
- Research Laboratory
- Others
By Regions
- 1. Market Overview
- 1.1. Introduction
- 1.2. Scope/Objective of the Study
- 1.2.1. Research Objective
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Demand of Rapid soluble drugs increase in elderly population
- 3.2.2. Increasing Rise in Rate of Adoption of Personalized Drugs Increase in Production of Combination Medicine
- 3.3. Market Challenges
- 3.3.1. Rising the Awareness about 3D Printing and Improvements in the Health Care Infrastructure
- 3.4. Market Trends
- 3.4.1. Introduction of 3D printed drugs by the players is rise in health care investment in emerging countries
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global 3D Printing Drug, by Type, Application and End User (value, volume and price ) (2016-2021)
- 5.1. Introduction
- 5.2. Global 3D Printing Drug (Value)
- 5.2.1. Global 3D Printing Drug by: Type (Value)
- 5.2.1.1. Spritam
- 5.2.1.2. Others
- 5.2.2. Global 3D Printing Drug by: Application (Value)
- 5.2.2.1. Neurology
- 5.2.2.2. Hearing and Audibility Aid
- 5.2.2.3. Dental, Medical Implants
- 5.2.2.4. Others
- 5.2.3. Global 3D Printing Drug by: End User (Value)
- 5.2.3.1. Hospitals
- 5.2.3.2. Clinics and
- 5.2.3.3. Research Laboratory
- 5.2.3.4. Others
- 5.2.1. Global 3D Printing Drug by: Type (Value)
- 5.3. Global 3D Printing Drug (Volume)
- 5.3.1. Global 3D Printing Drug by: Type (Volume)
- 5.3.1.1. Spritam
- 5.3.1.2. Others
- 5.3.2. Global 3D Printing Drug by: Application (Volume)
- 5.3.2.1. Neurology
- 5.3.2.2. Hearing and Audibility Aid
- 5.3.2.3. Dental, Medical Implants
- 5.3.2.4. Others
- 5.3.3. Global 3D Printing Drug by: End User (Volume)
- 5.3.3.1. Hospitals
- 5.3.3.2. Clinics and
- 5.3.3.3. Research Laboratory
- 5.3.3.4. Others
- 5.3.1. Global 3D Printing Drug by: Type (Volume)
- 5.4. Global 3D Printing Drug (Price)
- 5.4.1. Global 3D Printing Drug by: Type (Price)
- 6. 3D Printing Drug: Manufacturers/Players Analysis
- 6.1. Competitive Landscape
- 6.1.1. Market Share Analysis
- 6.1.1.1. Top 3
- 6.1.1. Market Share Analysis
- 6.2. Peer Group Analysis (2021)
- 6.3. BCG Matrix
- 6.4. Company Profile
- 6.4.1. Aprecia Pharmaceuticals (United States)
- 6.4.1.1. Business Overview
- 6.4.1.2. Products/Services Offerings
- 6.4.1.3. Financial Analysis
- 6.4.1.4. SWOT Analysis
- 6.4.2. Hewlett Packard Caribe (Netherlands)
- 6.4.2.1. Business Overview
- 6.4.2.2. Products/Services Offerings
- 6.4.2.3. Financial Analysis
- 6.4.2.4. SWOT Analysis
- 6.4.3. BV (Netherlands)
- 6.4.3.1. Business Overview
- 6.4.3.2. Products/Services Offerings
- 6.4.3.3. Financial Analysis
- 6.4.3.4. SWOT Analysis
- 6.4.4. LLC (United States)
- 6.4.4.1. Business Overview
- 6.4.4.2. Products/Services Offerings
- 6.4.4.3. Financial Analysis
- 6.4.4.4. SWOT Analysis
- 6.4.5. GlaxoSmithKline Plc. (United Kingdom)
- 6.4.5.1. Business Overview
- 6.4.5.2. Products/Services Offerings
- 6.4.5.3. Financial Analysis
- 6.4.5.4. SWOT Analysis
- 6.4.6. FabRx Ltd (United Kingdom)
- 6.4.6.1. Business Overview
- 6.4.6.2. Products/Services Offerings
- 6.4.6.3. Financial Analysis
- 6.4.6.4. SWOT Analysis
- 6.4.7. Cycle Pharmaceuticals (United Kingdom)
- 6.4.7.1. Business Overview
- 6.4.7.2. Products/Services Offerings
- 6.4.7.3. Financial Analysis
- 6.4.7.4. SWOT Analysis
- 6.4.1. Aprecia Pharmaceuticals (United States)
- 6.1. Competitive Landscape
- 7. Global 3D Printing Drug Sale, by Type, Application and End User (value, volume and price ) (2022-2027)
- 7.1. Introduction
- 7.2. Global 3D Printing Drug (Value)
- 7.2.1. Global 3D Printing Drug by: Type (Value)
- 7.2.1.1. Spritam
- 7.2.1.2. Others
- 7.2.2. Global 3D Printing Drug by: Application (Value)
- 7.2.2.1. Neurology
- 7.2.2.2. Hearing and Audibility Aid
- 7.2.2.3. Dental, Medical Implants
- 7.2.2.4. Others
- 7.2.3. Global 3D Printing Drug by: End User (Value)
- 7.2.3.1. Hospitals
- 7.2.3.2. Clinics and
- 7.2.3.3. Research Laboratory
- 7.2.3.4. Others
- 7.2.1. Global 3D Printing Drug by: Type (Value)
- 7.3. Global 3D Printing Drug (Volume)
- 7.3.1. Global 3D Printing Drug by: Type (Volume)
- 7.3.1.1. Spritam
- 7.3.1.2. Others
- 7.3.2. Global 3D Printing Drug by: Application (Volume)
- 7.3.2.1. Neurology
- 7.3.2.2. Hearing and Audibility Aid
- 7.3.2.3. Dental, Medical Implants
- 7.3.2.4. Others
- 7.3.3. Global 3D Printing Drug by: End User (Volume)
- 7.3.3.1. Hospitals
- 7.3.3.2. Clinics and
- 7.3.3.3. Research Laboratory
- 7.3.3.4. Others
- 7.3.1. Global 3D Printing Drug by: Type (Volume)
- 7.4. Global 3D Printing Drug (Price)
- 7.4.1. Global 3D Printing Drug by: Type (Price)
- 8. Appendix
- 8.1. Acronyms
- 9. Methodology and Data Source
- 9.1. Methodology/Research Approach
- 9.1.1. Research Programs/Design
- 9.1.2. Market Size Estimation
- 9.1.3. Market Breakdown and Data Triangulation
- 9.2. Data Source
- 9.2.1. Secondary Sources
- 9.2.2. Primary Sources
- 9.3. Disclaimer
- 9.1. Methodology/Research Approach
List of Tables
- Table 1. 3D Printing Drug: by Type(USD Million)
- Table 2. 3D Printing Drug: by Application(USD Million)
- Table 3. 3D Printing Drug: by End User(USD Million)
- Table 4. 3D Printing Drug Sales: by Type(N)
- Table 5. 3D Printing Drug Sales: by Application(N)
- Table 6. 3D Printing Drug Sales: by End User(N)
- Table 7. 3D Printing Drug: by Type(USD/Units)
- Table 8. Company Basic Information, Sales Area and Its Competitors
- Table 9. Company Basic Information, Sales Area and Its Competitors
- Table 10. Company Basic Information, Sales Area and Its Competitors
- Table 11. Company Basic Information, Sales Area and Its Competitors
- Table 12. Company Basic Information, Sales Area and Its Competitors
- Table 13. Company Basic Information, Sales Area and Its Competitors
- Table 14. Company Basic Information, Sales Area and Its Competitors
- Table 15. 3D Printing Drug: by Type(USD Million)
- Table 16. 3D Printing Drug: by Application(USD Million)
- Table 17. 3D Printing Drug: by End User(USD Million)
- Table 18. 3D Printing Drug Sales: by Type(N)
- Table 19. 3D Printing Drug Sales: by Application(N)
- Table 20. 3D Printing Drug Sales: by End User(N)
- Table 21. 3D Printing Drug: by Type(USD/Units)
- Table 22. Research Programs/Design for This Report
- Table 23. Key Data Information from Secondary Sources
- Table 24. Key Data Information from Primary Sources
List of Figures
- Figure 1. Porters Five Forces
- Figure 2. Supply/Value Chain
- Figure 3. PESTEL analysis
- Figure 4. Global 3D Printing Drug: by Type USD Million (2016-2021)
- Figure 5. Global 3D Printing Drug: by Application USD Million (2016-2021)
- Figure 6. Global 3D Printing Drug: by End User USD Million (2016-2021)
- Figure 7. Global 3D Printing Drug: by Type N (2016-2021)
- Figure 8. Global 3D Printing Drug: by Application N (2016-2021)
- Figure 9. Global 3D Printing Drug: by End User N (2016-2021)
- Figure 10. Global 3D Printing Drug: by Type USD/Units (2016-2021)
- Figure 11. Global 3D Printing Drug share by Players 2021 (%)
- Figure 12. Global 3D Printing Drug share by Players (Top 3) 2021(%)
- Figure 13. BCG Matrix for key Companies
- Figure 14. Aprecia Pharmaceuticals (United States) Revenue, Net Income and Gross profit
- Figure 15. Aprecia Pharmaceuticals (United States) Revenue: by Geography 2021
- Figure 16. Hewlett Packard Caribe (Netherlands) Revenue, Net Income and Gross profit
- Figure 17. Hewlett Packard Caribe (Netherlands) Revenue: by Geography 2021
- Figure 18. BV (Netherlands) Revenue, Net Income and Gross profit
- Figure 19. BV (Netherlands) Revenue: by Geography 2021
- Figure 20. LLC (United States) Revenue, Net Income and Gross profit
- Figure 21. LLC (United States) Revenue: by Geography 2021
- Figure 22. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
- Figure 23. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2021
- Figure 24. FabRx Ltd (United Kingdom) Revenue, Net Income and Gross profit
- Figure 25. FabRx Ltd (United Kingdom) Revenue: by Geography 2021
- Figure 26. Cycle Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
- Figure 27. Cycle Pharmaceuticals (United Kingdom) Revenue: by Geography 2021
- Figure 28. Global 3D Printing Drug: by Type USD Million (2022-2027)
- Figure 29. Global 3D Printing Drug: by Application USD Million (2022-2027)
- Figure 30. Global 3D Printing Drug: by End User USD Million (2022-2027)
- Figure 31. Global 3D Printing Drug: by Type N (2022-2027)
- Figure 32. Global 3D Printing Drug: by Application N (2022-2027)
- Figure 33. Global 3D Printing Drug: by End User N (2022-2027)
- Figure 34. Global 3D Printing Drug: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
- Aprecia Pharmaceuticals (United States)
- Hewlett Packard Caribe (Netherlands)
- BV (Netherlands)
- LLC (United States)
- GlaxoSmithKline Plc. (United Kingdom)
- FabRx Ltd (United Kingdom)
- Cycle Pharmaceuticals (United Kingdom)
Select User Access Type
Key Highlights of Report
Aug 2022
248 Pages
67 Tables
Base Year: 2021
Coverage: 15+ Companies; 18 Countries
Request Sample Pages
Budget constraints? Get in touch with us for special pricing
Check Discount Now
Talk to Our Experts
Want to Customize Study?
"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."
Frequently Asked Questions (FAQ):
The Global 3D Printing Drug market is predicted to grow at a CAGR of % between 2021 - 2027.
Global 3D Printing Drug market is restrained by 3D printing to Develop Illegal Drugs are Estimated to hamper the market..
The 3D Printing Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.